Stockreport

Arcus Biosciences (RCUS) Is Up 5.2% After Lung Trial Futility Results And Gilead Option Shift [Yahoo! Finance]

Arcus Biosciences, Inc.  (RCUS) 
Last arcus biosciences, inc. earnings: 3/5 04:10 pm Check Earnings Report
PDF metastatic non-small cell lung cancer after a pre-planned futility analysis, while reporting no new safety issues and confirming that zimberelimab plus chemotherapy show [Read more]